Sclerostin distribution in children and adolescents with type 1 diabetes mellitus and correlation with bone metabolism and bone mineral density

Pediatric Diabetes

Volumn 17, Issue 4, 2016, Pages 289-299

  Tsentidis, Charalampos ^a   Gourgiotis, Dimitrios ^a   Kossiva, Lydia ^a   Marmarinos, Antonios ^a   Doulgeraki, Artemis ^b   Karavanaki, Kyriaki ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

Adolescents; Bone metabolism; Children; Osteopenia; Sclerostin; Type 1 diabetes

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; SCLEROSTIN; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, HUMAN;

ADOLESCENT; ARTICLE; BONE DENSITY; BONE METABOLISM; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GROWTH ACCELERATION; HORMONE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; ADOLESCENT DEVELOPMENT; BLOOD; BONE DEVELOPMENT; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; GENETIC MARKER; WNT SIGNALING PATHWAY;

ADOLESCENT; ADOLESCENT DEVELOPMENT; BONE DENSITY; BONE DEVELOPMENT; BONE MORPHOGENETIC PROTEINS; BONE RESORPTION; CASE-CONTROL STUDIES; CHILD; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; GENETIC MARKERS; HUMANS; MALE; OSTEOGENESIS; WNT SIGNALING PATHWAY;

EID: 84931431224     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12288     Document Type: Article

References (39)

1. Rakel A, Sheehy O, Rahme E, LeLorier J. Osteoporosis among patients with type 1 and type 2 diabetes. Diabetes Metab 2008: 34: 193-205.
2. Sealand R, Razavi C, Adler RA. Diabetes mellitus and osteoporosis. Curr Diab Rep 2013: 13: 411-418.
3. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007: 166: 495-505.
4. Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 2009: 84: 45-55.
5. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis. Osteoporos Int 2007: 18: 427-444.
6. Yan W, Li X. Impact of diabetes and its treatments on skeletal diseases. Front Med 2013: 7: 81-90.
7. Starup-Linde J. Diabetes, biochemical markers of bone turnover, diabetes control, and bone. Front Endocrinol 2013: 4: 21.
8. Jackuliak P, Payer J. Osteoporosis, fractures, and diabetes. Int J Endocrinol 2014: 2014: 820615.
9. Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007: 148: 2635-2643.
10. Kusu N, Laurikkala J, Imanishi M et al. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 2003: 278: 24113-24117.
11. Li X, Zhang Y, Kang H et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005: 280: 19883-19887.
12. Winkler D, Sutherland MK, Geoghegan JC et al. Osteocyte control of bone formation via sclerostin. EMBO J 2003: 22: 6267-6276.
13. van Bezooijen RL, Roelen BA, Visser A et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004: 199: 805-814.
14. Portal-Nunez S, Lozano D, de Castro LF, de Gortazar AR, Nogues X, Esbrit P. Alterations of the Wnt/beta-catenin pathway and its target genes for the N- and C-terminal domains of parathyroid hormone-related protein in bone from diabetic mice. FEBS Lett 2010: 584: 3095-3100.
15. Gennari L, Merlotti D, Valenti R et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 2012: 97: 1737-1744.
16. Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2012: 97: 234-241.
17. van Lierop AH, Hamdy NA, van der Meer RW et al. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. Eur J Endocrinol 2012: 166: 711-716.
18. Gaudio A, Privitera F, Battaglia K et al. Sclerostin levels associated with inhibition of the Wnt/beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012: 97: 3744-3750.
19. Catalano A, Pintaudi B, Morabito N et al. Gender differences in sclerostin and clinical characteristics in type 1 diabetes mellitus. Eur J Endocrinol 2014: 171: 293-300.
20. Neumann T, Hofbauer LC, Rauner M et al. Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus. Clin Endocrinol (Oxf) 2014: 80: 649-655.
21. Gaudio A, Privitera F, Pulvirenti I, Canzonieri E, Rapisarda R, Fiore CE. The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus. Diab Vasc Dis Res 2014: 11: 48-52.
22. Kim SH, Yoon SY, Lim SK, Rhee Y. The effect of renal dysfunction on circulating sclerostin level in patients with type 2 diabetes. Int J Endocrinol 2014: 2014: 715908.
23. Avgerinos A, Argiropoulou EC, Almond L, Michalopoulou M. A new instrument for evaluating energy expenditure: convergent validity and reliability of the physical activity and lifestyle questionnaire (PALQ). Sport Perform Health 2000: 4: 281-300.
24. Magkos F, Manios Y, Babaroutsi E, Sidossis LS. Development and validation of a food frequency questionnaire for assessing dietary calcium intake in the general population. Osteoporos Int 2006: 17: 304-312.
25. Kirmani S, Amin S, McCready LK et al. Sclerostin levels during growth in children. Osteoporos Int 2012: 23: 123-1130.
26. Modder UI, Clowes JA, Hoey K et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res 2011: 26: 27-34.
27. Codner E, Cassorla F. Puberty and ovarian function in girls with type 1 diabetes mellitus. Horm Res 2009: 71: 12-21.
28. Rogol AD, Roemmich JN, Clark PA. Growth at puberty. J Adolesc Health 2002: 31: 192-200.
29. Kanbur NÖ, Derman O, Kinik E. The relationships between pubertal development, IGF-1 axis, and bone formation in healthy adolescents. J Bone Miner Metab 2005: 23: 76-83.
30. Amrein K, Amrein S, Drexler C et al. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab 2012: 97: 148-154.
31. Modder UI, Hoey KA, Amin S et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 2011: 26: 373-379.
32. van Lierop AH, Witteveen JE, Hamdy NA, Papapoulos SE. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol 2010: 163: 833-837.
33. Register TC, Hruska KA, Divers J et al. Sclerostin is positively associated with bone mineral density in men and women and negatively associated with carotid calcified atherosclerotic plaque in men from the African American-Diabetes Heart Study. J Clin Endocrinol Metab 2014: 99: 315-321.
34. Morales-Santana S, Garcia-Fontana B, Garcia-Martin A et al. Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care 2013: 36: 1667-1674.
35. Heilmeier U, Carpenter DR, Patsch JM et al. Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures. Osteoporos Int 2015: 26: 1283-1293.
36. Ardawi MS, Akhbar DH, Alshaikh A et al. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone 2013: 56: 355-362.
37. Yamamoto M, Yamauchi M, Sugimoto T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013: 98: 4030-4037.
38. Rubin MR. Bone cells and bone turnover in diabetes mellitus. Curr Osteoporos Rep 2015: 13:186-191.
39. Drake MT, Srinivasan B, Modder UI et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 2010: 95: 5056-5062.